Date: Thu 21 Jun 2012
Source: Eurosurveillance Edition 2012, 17(25) [edited]
Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011
[Authors: Unemo M, Golparian D, Potocnik M, Jeverica S]
We describe the 2nd case in Europe of verified treatment failure of pharyngeal gonorrhea, caused by an internationally occurring multidrug-resistant gonococcal clone, with recommended 1st-line ceftriaxone 250 mg in Slovenia. This is of grave concern since ceftriaxone is last remaining option for empirical treatment. Increased awareness of ceftriaxone failures, more frequent test-of-cure, strict adherence to regularly updated treatment guidelines, and thorough verification/falsification of suspected treatment failures are essential globally. New effective treatment options are imperative.
_Neisseria gonorrhoeae_ has developed resistance to all antimicrobial drugs previously used as 1st-line treatment (1). Resistance to currently recommended 1st-line 3rd-generation cephalosporins, cefixime, and ceftriaxone, is emerging (1-3), and treatment failures with cefixime have been verified in Japan (4) and several European countries, namely Norway (5), the UK (6), Austria (7), and France (8). One failure to treat pharyngeal gonorrhea with ceftriaxone, the last remaining option for empiric treatment, has also been verified in Europe (Sweden) (9). It is likely that treatment failures with ceftriaxone will initially accumulate for pharyngeal gonorrhea because these infections are harder to treat than urogenital infections (1,10,11). It is of grave concern that during the past year, the 1st 3 extensively drug-resistant (XDR) (1) _N. gonorrhoeae_ strains that also had high-level ceftriaxone resistance were reported from Japan, France and Spain (8,12,13).
In this emergent situation of fear that gonorrhoea may become untreatable (1,8,12), the European Centre for Disease Prevention and Control (ECDC) has prepared a response plan for the European Union (14). The WHO has published the 'Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in _Neisseria gonorrhoeae_' (15).
This report describes a ceftriaxone treatment failure of pharyngeal gonorrhea in Slovenia in 2011, which is the 2nd one strictly verified in Europe (and possibly globally).
In early September 2011, a Slovenian bisexual woman in her early 30s visited a dermatovenereologist in Ljubljana, Slovenia (day 1). She had no symptoms of gonorrhea, however, she was sampled and administered the internationally recommended 1st-line treatment of 1Ã--250 mg ceftriaxone intramuscularly (table [for tables, see source URL above. - Mod.LL]), based on the fact that she had had unprotected oral and vaginal sex with gonorrhea-positive casual male partner in late August 2011 in Belgrade, Serbia. The partner could later not be traced in Serbia.
Microscopy of Gram stained smear of a cervical specimen was negative for _N. gonorrhoeae_. However, 2 days later (day 3), a pharyngeal culture was shown to be positive for _N. gonorrhoeae_, while the cervical culture was negative. _Chlamydia trachomatis_ DNA was identified in an additional cervical sample, using the COBAS TaqMan CT Test v2.0 (Roche Diagnostics). During a follow-up visit 7 days after the initial visit (day 8), a test-of-cure (TOC) pharyngeal culture was taken and examination showed no signs or symptoms of pharyngeal gonorrhea, and she was given doxycycline at a dosage of 100 mg twice a day, for 7 days, for a concomitant chlamydial infection. However, 2 days later (day 10) the TOC culture confirmed gonococci in a pharyngeal sample. About 3 weeks later (day 30), the patient returned with symptoms of acute pharyngitis (pain, inflammation and fever) and was given a dose of 250 mg ceftriaxone intramuscularly and an oral dose of 1 g azithromycin. Finally, a follow-up examination after about 4 months (day 173) showed no signs of infection, and a pharyngeal TOC culture was negative for _N. gonorrhoeae_. The patient repeatedly reassured that she had not had any sexual contacts between the ceftriaxone therapy and the TOC.
Characterisation of _N. gonorrhoeae_ isolates
The pre- and post-treatment _N. gonorrhoeae_ isolates were species-confirmed by sugar utilisation test and Phadebact Monoclonal GC Test (Pharmacia Diagnostics). The isolates were indistinguishable using serovar determination (Bpyut), full-length porB gene sequencing, multilocus sequence typing (MLST; ST1901 (12), and _N. gonorrhoeae_ multiantigen sequence typing (NG-MAST; ST1407 ). Using Etest (AB bioMerieux), both isolates showed a ceftriaxone minimum inhibitory concentration (MIC) of 0.125 mg/L (Table), and overall indistinguishable antibiograms (cefixime 0.25 mg/L, spectinomycin 16 mg/L, azithromycin 0.5 mg/L, and ciprofloxacin more than 32 mg/L) and were beta-lactamase-negative. According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (17), the MIC of ceftriaxone for these isolates were equal to the resistance breakpoint ( greater than 0.125 mg/L). Sequencing of resistance determinants for 3rd-generation cephalosporins (1,8,12,18,19) showed that both isolates contained an identical penA mosaic allele XXXIV (12), which has been correlated with decreased susceptibility or resistance to 3rd-generation cephalosporins and treatment failure with cefixime (5,20,21). In addition, they contained mtrR and penB alterations that further increase the MICs of 3rd-generation cephalosporins (1,8,12,19).
This study describes the 2nd verified case in Europe (possibly globally) of treatment failure of pharyngeal gonorrhea with the internationally recommended 1st-line treatment of 250 mg ceftriaxone, the last remaining treatment option. The failure was strictly verified in accordance with WHO recommendations (1,15), that is, detailed clinical records were obtained, reinfection was excluded as much as possible, pre- and post-treatment isolates were indistinguishable using highly discriminatory typing, ceftriaxone MICs were elevated, and the isolates contained well-known cephalosporin resistance determinants. The reporting of the case was unfortunately delayed because it took several months before the patient returned for follow-up examination and TOC after the 3rd antimicrobial treatment (to prove successful eradication of infections).
This case shows that ceftriaxone at a dosage of 1Ã--250 mg may in rare cases not be enough for treatment of pharyngeal gonorrhea caused by gonococcal strains with ceftriaxone MICs of 0.125 mg/L. A 250 mg ceftriaxone dose also results in median times of free ceftriaxone above the MIC of only 24.1 h (range: 10.5-52.2 h) for the detected MIC of 0.125 mg/L (22), and rare treatment failures may happen in the lower range. Nevertheless, these cases are likely to be treatable with enhanced ceftriaxone doses or dual antimicrobial treatment that has already been introduced as 1st-line empiric treatment in the USA (10) and the UK (23). It may be crucial to promptly revise also other national and regional treatment guidelines, and a revision of the European guidelines from the International Union against Sexually Transmitted Infections (IUSTI) and WHO (2) are currently in progress.
It is worrying that the gonococcus causing this treatment failure was assigned to MLST ST1901 and NG-MAST ST1407, which is a multidrug-resistant gonococcal clone that also shows decreased susceptibility and resistance to cefixime and is spreading worldwide (5,7,8,13,20,21,24-28). The previously reported treatment failures with cefixime in Norway (5), Austria (7), France (8), and likely in the UK (6), were caused by this gonococcal clone or its evolving subtypes. This clone has also shown its capacity to develop high-level resistance to ceftriaxone (8,13).
In conclusion, the 2nd case in Europe (possibly worldwide) of clinical failure using standard ceftriaxone treatment for pharyngeal gonorrhea, caused by an internationally occurring multidrug-resistant gonococcal clone, has been strictly verified in Slovenia. An increased awareness of treatment failures with ceftriaxone, more frequent TOC (all cases of pharyngeal cases may be crucial), strict adherence to appropriate treatment guidelines, which need to be regularly updated based on antimicrobial resistance surveillance data, and thorough verification/falsification of suspected treatment failures (including subsequent tracing of sexual contacts of the index case with the treatment failure) are essential globally. A stronger focus on pharyngeal gonorrhea, including increased sampling of pharyngeal specimens and promotion of condom use also when practising oral sex, is also crucial because pharyngeal infection is harder to treat than urogenital infection, relatively common, and is frequently an asymptomatic reservoir for infection and emergence of resistances (1,5). Ultimately, new options for effective treatment of gonorrhea are imperative.
1. Tapsall JW, Ndowa F, Lewis DA, Unemo M: Meeting the public health challenge of multidrug- and extensively drug-resistant _Neisseria gonorrhoeae_. Expert Rev Anti Infect Ther. 2009; 7: 821-34.
2. Bignell C, IUSTI/WHO: 2009 European (IUSTI/WHO) guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2009; 20: 453-7.
4. Yokoi S, Deguchi T, Ozawa T, et al: Threat to cefixime treatment of gonorrhea. Emerg Infect Dis. 2007; 13: 1275-7.
8. Unemo M, Golparian D, Nicholas R, et al: High-level cefixime- and ceftriaxone-resistant _N. gonorrhoeae_ in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012; 56: 1273-80.
10. Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC): Sexually transmitted diseases treatment guidelines, 2010. MMWR. 2010; 59(RR-12): 1-110. Available from <http://www.cdc.gov/std/treatment/2010/
11. Moran JS: Treating uncomplicated _Neisseria gonorrhoeae_infections: is the anatomic site of infection important? Sex Transm Dis. 1995; 22: 39-47.
12. Ohnishi M, Golparian D, Shimuta K, et al: Is _Neisseria gonorrhoeae_ initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011; 55: 3538-45.
13. Camara J, Serra J, Ayats J, et al: Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother. 2012 May 7. [Epub ahead of print].
16. Unemo M, Sjostrand A, Akhras M, et al: Molecular characterization of _Neisseria gonorrhoeae_ identifies transmission and resistance of one ciprofloxacin-resistant strain. APMIS. 2007; 115: 231-41.
18. Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J: Phenotypic and genetic characterization of the 2008 WHO _Neisseria gonorrhoeae_ reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother. 2009; 63: 1142-51.
19. Zhao S, Duncan M, Tomberg J, et al: Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in _Neisseria gonorrhoeae_. Antimicrob Agents Chemother. 2009; 53: 3744-51.
20. Buono S, Wu A, Hess DC, et al: Using the _Neisseria gonorrhoeae_ Multiantigen Sequence-Typing Method to Assess Strain Diversity and Antibiotic Resistance in San Francisco, California. Microb Drug Resist. 2012 Jun 11. [Epub ahead of print].
21. Heymans R, Bruisten SM, Golparian D, et al: Clonally related _Neisseria gonorrhoeae_ isolates with decreased susceptibility to the extended-spectrum cephalosporin cefotaxime in Amsterdam, the Netherlands. Antimicrob Agents Chemother. 2012;56: 1516-22.
22. Chisholm SA, Mouton JW, Lewis DA, et al: Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother. 2010;65: 2141-8.
23. Bignell C, Fitzgerald M, Guideline Development Group: UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS. 2011; 22: 541-7.
24. Golparian D, Hellmark B, Fredlund H, Unemo M: Emergence, spread and characteristics of _Neisseria gonorrhoeae_ isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. Sex Transm Infect. 2010; 86: 454-60.
25. Pandori M, Barry PM, Wu A, et al: Mosaic penicillin-binding protein 2 in _Neisseria gonorrhoeae_ isolates collected in 2008 in San Francisco, California. Antimicrob Agents Chemother. 2009; 53; 4032-4.
26. Tapsall JW, Ray S, Limnios A: Characteristics and population dynamics of mosaic penA allele-containing _Neisseria gonorrhoeae_ isolates collected in Sydney, Australia, in 2007-2008. Antimicrob
Agents Chemother. 2010; 54: 554-6.
27. Tanaka M, Koga Y, Nakayama H, et al: Antibiotic-resistant phenotypes and genotypes of _Neisseria gonorrhoeae_ isolates in Japan: identification of strain clusters with multidrug-resistant phenotypes. Sex Transm Dis. 2011; 38: 871-5.
28. _Neisseria gonorrhoeae_ Multi Antigen Sequence Typing (NG-MAST). Query global sequence and ST database. London: Department of Infectious Disease Epidemiology, Imperial College London and are funded by The Wellcome Trust. Available from <http://www.ng-mast.net/sql/allelicprofile.asp
[For a discussion of reduced cephalosporin susceptibility among _N. gonorrhoeae_ isolates in the United States, see CDC Morbidity and Mortality Weekly Report (MMWR) 8 Jul 2011; 60(26): 873-7 (<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6026a2.htm
>). - ProMed Mod.LL]